{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:03:58Z","timestamp":1791576238543,"version":"4.3.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thrombosis Research Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Guidelines do not recommend to take pattern of atrial fibrillation (AF) into account for the indication of anticoagulation (AC). We assessed AF pattern and the risk of cardiovascular events during 2-years of follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We categorized AF as paroxysmal, persistent, or permanent in 29 181 patients enrolled (2010\u201315) in the Global Anticoagulant Registry In the FIELD of AF (GARFIELD-AF). We used multivariable Cox regression to assess the risks of stroke\/systemic embolism (SE) and death across patterns of AF, and whether this changed with AC on outcomes. Atrial fibrillation pattern was paroxysmal in 14 344 (49.2%), persistent in 8064 (27.6%), and permanent 6773 (23.2%) patients. Median CHA2DS2-VASc, GARFIELD-AF, and HAS-BLED scores assessing the risk of stroke\/SE and\/or bleeding were similar across AF patterns, but the risk of death, as assessed by the GARFIELD-AF risk calculator, was higher in non-paroxysmal than in paroxysmal AF patterns. During 2-year follow-up, after adjustment, non-paroxysmal AF patterns were associated with significantly higher rates of all-cause death, stroke\/SE, and new\/worsening congestive heart failure (CHF) than paroxysmal AF in non-anticoagulated patients only. In anticoagulated patients, a significantly higher risk of death but not of stroke\/SE and new\/worsening CHF persisted in non-paroxysmal compared with paroxysmal AF patterns.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In non-anticoagulated patients, non-paroxysmal AF patterns were associated with higher risks of stroke\/SE, new\/worsening HF and death than paroxysmal AF. In anticoagulated patients, the risk of stroke\/SE and new\/worsening HF was similar across all AF patterns. Thus AF pattern is no longer prognostic for stroke\/SE when patients are treated with anticoagulants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>URL: http:\/\/www.clinicaltrials.gov. Unique identifier: NCT01090362.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euz292","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T04:16:38Z","timestamp":1570508198000},"page":"195-204","source":"Crossref","is-referenced-by-count":34,"title":["The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8793","authenticated-orcid":false,"given":"Dan","family":"Atar","sequence":"first","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital, Kirkeveien 166, NO-0407 Oslo, Norway"},{"name":"Department of Cardiology, Institute of Clinical Sciences, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-2798","authenticated-orcid":false,"given":"Eivind","family":"Berge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital, Kirkeveien 166, NO-0407 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Le Heuzey","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Georges Pompidou Hospital, Ren\u00e9 Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Virdone","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Thrombosis Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A John","family":"Camm","sequence":"additional","affiliation":[{"name":"Department of Clinical Cardiology, St. George\u2019s University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital, Zurich, CH, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Vascular Laboratory, The Alfred Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z","family":"Goldhaber","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology), Tokai University, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Kayani","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Thrombosis Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Misselwitz","sequence":"additional","affiliation":[{"name":"Therapeutic areas Thrombosis & Hematology, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Stepinska","sequence":"additional","affiliation":[{"name":"Department of Intensive Cardiac Therapy, Institute of Cardiology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G G","family":"Turpie","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bassand","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Thrombosis Research Institute, London, UK"},{"name":"Department of Cardiology, University of Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Thrombosis Research Institute, London, UK"},{"name":"Department of Surgery, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the GARFIELD-AF Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"2020021221481931000_euz292-B1"},{"key":"2020021221481931000_euz292-B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2020021221481931000_euz292-B3","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.ijcard.2012.06.118","article-title":"Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project","volume":"167","author":"Banerjee","year":"2013","journal-title":"Int J Cardiol"},{"key":"2020021221481931000_euz292-B4","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/eurheartj\/ehw007","article-title":"The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis","volume":"37","author":"Ganesan","year":"2016","journal-title":"Eur Heart J"},{"key":"2020021221481931000_euz292-B5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehn101","article-title":"Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?","volume":"29","author":"Nieuwlaat","year":"2008","journal-title":"Eur Heart J"},{"key":"2020021221481931000_euz292-B6","doi-asserted-by":"crossref","first-page":"e63479.","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS One"},{"key":"2020021221481931000_euz292-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: global Anticoagulant Registry in the FIELD (GARFIELD)","volume":"163","author":"Kakkar","year":"2012","journal-title":"Am Heart J"},{"key":"2020021221481931000_euz292-B8","doi-asserted-by":"crossref","first-page":"e017157.","DOI":"10.1136\/bmjopen-2017-017157","article-title":"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation","volume":"7","author":"Fox","year":"2017","journal-title":"BMJ Open"},{"key":"2020021221481931000_euz292-B9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2020021221481931000_euz292-B10","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004267","article-title":"Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)","volume":"10","author":"Link","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2020021221481931000_euz292-B11","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/STROKEAHA.115.009487","article-title":"Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: AMADEUS trial","volume":"46","author":"Senoo","year":"2015","journal-title":"Stroke"},{"key":"2020021221481931000_euz292-B12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial","volume":"36","author":"Steinberg","year":"2015","journal-title":"Eur Heart J"},{"key":"2020021221481931000_euz292-B13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","article-title":"Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES","volume":"36","author":"Vanassche","year":"2015","journal-title":"Eur Heart J"},{"key":"2020021221481931000_euz292-B14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004847","article-title":"Not all types of atrial fibrillation carry the same stroke risk, but most benefit from oral anticoagulation","volume":"10","author":"Hohnloser","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2020021221481931000_euz292-B15","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1161\/STROKEAHA.116.013746","article-title":"Higher risk of ischemic events in secondary prevention for patients with persistent than those with paroxysmal atrial fibrillation","volume":"47","author":"Koga","year":"2016","journal-title":"Stroke"},{"key":"2020021221481931000_euz292-B16","doi-asserted-by":"crossref","first-page":"648.1","DOI":"10.1093\/europace\/euv390","article-title":"\u2018Real-world\u2019 management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry","volume":"18","author":"Boriani","year":"2016","journal-title":"Europace"},{"key":"2020021221481931000_euz292-B17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehn599","article-title":"Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation","volume":"31","author":"Friberg","year":"2010","journal-title":"Eur Heart J"},{"key":"2020021221481931000_euz292-B18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2796.2007.01909.x","article-title":"Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation","volume":"264","author":"Lip","year":"2008","journal-title":"J Intern Med"},{"key":"2020021221481931000_euz292-B19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jamacardio.2018.1176","article-title":"Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study","volume":"3","author":"Go","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2020021221481931000_euz292-B20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2020021221481931000_euz292-B21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/1871529X17666170104120746","article-title":"Biomarker assays for personalised stroke risk assessment in atrial fibrillation","volume":"17","author":"Hall","year":"2017","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"2020021221481931000_euz292-B22","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"2020021221481931000_euz292-B23","doi-asserted-by":"crossref","first-page":"e0191592.","DOI":"10.1371\/journal.pone.0191592","article-title":"Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation","volume":"13","author":"Bassand","year":"2018","journal-title":"PLoS One"},{"key":"2020021221481931000_euz292-B24","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"37","author":"Bassand","year":"2016","journal-title":"Eur Heart J"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/22\/2\/195\/32360063\/euz292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/22\/2\/195\/32360063\/euz292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T21:55:32Z","timestamp":1581544532000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/22\/2\/195\/5634164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,11,20]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euz292","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,11,20]]}}}